Integration of Pharmaceutical Discovery and Development Case Histories /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer US : Imprint: Springer,
1998.
|
| Edición: | 1st ed. 1998. |
| Colección: | Pharmaceutical Biotechnology,
11 |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/b114429 |
Tabla de Contenidos:
- Renin Inhibitors
- The Discovery and Development of Angiotensin II Antagonists
- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor
- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707
- Endothelin Receptor Antagonists
- LHRH Antagonists
- LHRH Agonists
- Discovery and Development of Somatostatin Agonists
- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors
- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development
- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule
- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate
- Famciclovir
- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics
- Hematoregulators
- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase
- Discovery of a Potent and Selective ?1A Antagonist
- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2
- The Anxieties of Drug Discovery and Development
- CI-1015
- Orally Active Nonpeptide CCK-A Agonists
- Orally Active Growth Hormone Secretagogues
- Dorzolamide, a 40-Year Wait
- Discovery and Development of Novel Melanogenic Drugs.